(IN BRIEF) GSK has entered into a multi-programme development and licensing agreement with Hengrui Pharma to advance up to 12 innovative therapies, including HRS-9821, a potentially best-in-class PDE3/4 inhibitor currently in clinical trials for COPD. The deal includes $500 million … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI-era medicine, biopharma partnership, Chronic obstructive pulmonary disease, clinical development, cloud healthcare, COPD treatment, drug innovation, drug pipeline, dry powder inhaler, Frank Jiang, global health, GSK, Hart-Scott-Rodino Act, Hengrui Pharma, HRS-9821, immunology, inflammation, licensing agreement, milestone payments, novel therapeutics, oncology, partnership, PDE3/4 inhibitor, pharmaceutical collaboration, phase I trials, respiratory medicine, Tony Wood
(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI drug discovery, biotech partnerships, Bristol-Myers Squibb, CELMoD, Cord Dohrmann, E3 ligase, Evotec, first-in-class, milestone payments, molecular glue degraders, oncology, PanOmics, partnership, pharmaceutical R&D, protein degradation, targeted therapies, unmet medical needs
(IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged autoimmune diseases, B cell depletion, biologics innovation, biopharma collaboration, bispecific compound, Boehringer Ingelheim, Carine Boustany, chronic disease treatment, Cue Biopharma, CUE-501, Daniel Passeri, drug development, Immuno-STAT, Immuno-STAT platform, immunology pipeline, inflammatory diseases, licensing agreement, memory T cells, milestone payments, partnership, precision medicine, royalty payments, strategic partnership, T cell engagers, targeted biologics, up-front payment
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?